EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Intranasal delivery of a ROS-activatable myeloperoxidase inhibitor alleviates Alzheimer’s-like symptoms and pathology

Jing Wang iD, Peilin Cong iD, Enduo Feng, Matthias W G Zeller, Boyu Zhang, Yifan Lv iD, Negin Jalali Motlagh, Jenny Linnoila, Han Wang iD, Cuihua Wang iD, Zhiming Xu, Ke Gao iD und 6 weitere

Proceedings of the National Academy of Sciences · 24.11.2026 · 123 (47)

DOI: 10.1073/pnas.2603280123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 17.11.2026. Verfasst von Jing Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Reactive Oxygen Species, Peroxidase, Enzyme Inhibitors. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS), HHS | NIH | National Institute on Aging (NIA), STCSM | Natural Science Foundation of Shanghai Municipality ().

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic neuroinflammation and oxidative stress are important contributors to Alzheimer’s disease (AD). Myeloperoxidase (MPO), a key driver of oxidative inflammation released mainly by activated microglia in the neurodegenerative brain, is a potential therapeutic target to inhibit the neuroinflammatory cascade and oxidative damage in AD, but the underlying mechanisms remain unexplored, and achieving targeted brain delivery of an MPO inhibitor and minimizing systemic effects remain significant challenges. We addressed these limitations by first establishing that genetic deletion of MPO in the 5XFAD mouse model improved memory performance and reduced amyloid deposition, validating MPO as a therapeutic target. We then developed a liposome-encapsulated reactive oxygen species (ROS)-activatable MPO inhibitor (LERAMI). LERAMI uniquely combines targeted delivery with on-demand drug release, utilizing a ROS-sensitive linker to selectively release MPO inhibitors in ROS-rich regions within the AD microenvironment, minimizing off-target effects and systemic toxicity. In the 5XFAD mouse model. By reducing MPO expression and activity, LERAMI significantly improved cognitive performance, accompanied by decreased microglial activation, attenuated oxidative DNA damage, improved synaptic and neuronal density, and reduced amyloid burden. RNA sequencing revealed a robust hippocampal transcriptomic reprogramming, with upregulation of pathways critical for synaptic plasticity, calcium signaling, axon guidance, and neuroprotection, along with downregulation of inflammatory and immune response pathways. These findings demonstrate that targeted ROS-activatable MPO inhibition with LERAMI represents a promising therapeutic strategy for AD and potentially other neuroinflammatory diseases, offering a unique approach to mitigate neuroinflammation, preserve synaptic integrity, and restore cognitive function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseReactive Oxygen SpeciesPeroxidaseEnzyme InhibitorsAnimalsMiceAdministration, IntranasalDisease Models, AnimalOxidative StressMice, TransgenicHumansMicrogliaLiposomesBrain

Stichwörter der Autor:innen

Alzheimer’s diseaseROSmyeloperoxidasenano-drugneuroinflammation

Substanzen

Reactive Oxygen SpeciesPeroxidaseEnzyme InhibitorsLiposomes

Autor:innen und Institutionen

  • Department of Radiology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.
  • Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.
  • Center for Interdisciplinary Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129.
  • Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Department of Anaesthesiology and Perioperative Medicine, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.

ORCID-Profile: Jing Wang, Peilin Cong, Yifan Lv, Han Wang, Cuihua Wang, Ke Gao, Yu Luo, He Wang, Dalong Ni, John W Chen

Förderung

  • HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
  • HHS | NIH | National Institute on Aging (NIA)
  • STCSM | Natural Science Foundation of Shanghai Municipality ()
  • MOST | National Natural Science Foundation of China (NSFC)
  • Tongji University Medicine-X Interdisciplinary Research Initiative

Zitieren

APA

Wang, J., Cong, P., Feng, E., Zeller, M. W. G., Zhang, B., Lv, Y., Motlagh, N. J., Linnoila, J., Wang, H., Wang, C., Xu, Z., Gao, K., Chen, Q., Luo, Y., Wang, H., Ni, D., Xiong, L., & Chen, J. W. (2026). Intranasal delivery of a ROS-activatable myeloperoxidase inhibitor alleviates Alzheimer’s-like symptoms and pathology. Proceedings of the National Academy of Sciences, 123(47). https://doi.org/10.1073/pnas.2603280123

Vancouver

Wang J, Cong P, Feng E, Zeller MWG, Zhang B, Lv Y, et al. Intranasal delivery of a ROS-activatable myeloperoxidase inhibitor alleviates Alzheimer’s-like symptoms and pathology. Proceedings of the National Academy of Sciences. 2026;123(47). doi:10.1073/pnas.2603280123

BibTeX
@article{Wang2026,
  author = {Wang, Jing and Cong, Peilin and Feng, Enduo and Zeller, Matthias W G and Zhang, Boyu and Lv, Yifan and Motlagh, Negin Jalali and Linnoila, Jenny and Wang, Han and Wang, Cuihua and Xu, Zhiming and Gao, Ke and Chen, Qian and Luo, Yu and Wang, He and Ni, Dalong and Xiong, Lize and Chen, John W},
  title = {Intranasal delivery of a ROS-activatable myeloperoxidase inhibitor alleviates Alzheimer’s-like symptoms and pathology},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {47},
  doi = {10.1073/pnas.2603280123}
}
Kostenlos starten →